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In a previous study, Dutch children with phenylketonuria (PKU) were found to be slightly 
shorter than their healthy counterparts. In the literature, it has been hypothesised that a 
higher protein intake is necessary to optimize growth in PKU patients. The study aimed 
to investigate whether protein intake (total, natural and protein substitute) in this group 
might be an explanatory factor for the observed growth. Growth of height and head 
circumference and dietary data on protein intake (total, natural and protein substitute) 
from 174 Dutch PKU patients born between 1974 and 1996 were analysed retrospectively 
for the patients’ ﬁ rst three years of life. Analyses were corrected for energy intake during the 
ﬁ rst year of life and for the clinical severity of the deﬁ ciency of phenylalanine hydroxylase 
by means of plasma phenylalanine concentration at birth. 
Neither protein nor energy intake correlated with height growth. A positive, statistically 
signiﬁ cant relation between head circumference growth and natural protein and total 
protein intake was found, but not with the intake of the protein substitute or energy. 
Therefore, this study suggests that improvement of the protein substitute rather than an 
increase of total protein intake may be important to optimise head circumference growth 
in PKU patients.
INTRODUCTION
Phenylketonuria (PKU) is caused by a deﬁ ciency of the hepatic enzyme 
phenylalanine hydroxylase (PAH). Treatment of PKU aims at lowering plasma 
phenylalanine (Phe) concentrations by dietary Phe restriction 1. Since Phe is part of 
natural protein, Phe restriction implies restriction of natural protein. Consequently, PKU 
patients consume individually tailored limited amounts of natural protein so that Phe 
requirements are just met. The requirement for the remaining essential amino acids 
and nitrogen is fulﬁ lled in the form of a protein substitute containing all amino acids but 
Phe, and minerals, vitamins and other micronutrients, that constitute natural protein 
sources. This treatment has proven its effectiveness in preventing mental retardation, 
although defects in neuropsychological functioning remain1;2.
Restriction of protein intake during infancy carries the risk of negative effects 
on growth of height and head circumference, as well as negative effects on 
neurodevelopment and immunity, growth being probably the latest characteristic 
affected 3. In early reports of the collaborative study group of the USA on PKU 
treatment, restriction of height as well as head circumference occurred, but in later 
reports of that group this observation was not reported4;5. Verkerk and colleagues 
(1994) showed that Dutch patients treated for PKU have a lower mean height and 
head circumference at the time of diagnosis. In the ﬁ rst three years of life, further 
height growth restriction occurred while head circumference normalised in most 
children 6. This ﬁ nding prompted a search for factors that might be responsible for the 
restriction in growth in the Dutch PKU population. Studies that investigated causes for 
the retarded height growth in PKU patients focused on low blood Phe concentrations, 
a deﬁ ciency of Tyr, or a deﬁ cient intake of total protein. The ﬁ rst two suggestions could 
not be shown to cause growth restriction in length5;7;8. 
The recommended protein intake of PKU infants is the subject of ongoing debate9-








11. Most studies investigating the effects of the dietary treatment on growth in PKU 
have focused predominantly on the restriction in height growth 5;8;12. A smaller number 
of studies focused on the relation of head circumference and protein intake in PKU 
infants, but the results of these studies were not conclusive13-15. 
Theoretically, the conclusion that the total protein intake is not related to growth 
does not exclude the possibility of a relation with one of the two fractions of the 
protein PKU patients consume, i.e. the natural protein and the protein substitute 11;16. 
The ﬁ nding of Acosta and collegues, that growth is related to total protein may also 
be explained by a relation with either one of these components rather than the total 
intake. Speciﬁ cation of the possible relation between growth and protein intake 
would be of biological, social and economic interest. An increase in total protein 
intake will especially increase the intake of the chemically manufactured protein 
substitute. Protein substitutes have unpleasant taste and are expensive. A relation 
with natural protein rather than total protein would favour research to further optimize 
the biological composition of protein substitutes. To our knowledge, no study has 
paid special attention to the speciﬁ c amount of protein obtained from the protein 
substitute or the amount of natural protein in relation to growth of either height or 
head circumference in PKU infants.
The aim of this study was to determine the relation between the intake of the total 
amount of protein, the amount of protein substitute, and the amount of natural protein 
on the one hand, and growth of height and head circumference on the other hand in 
a large group of early diagnosed and continuously treated Dutch PKU patients during 
the ﬁ rst three years of life. The hypothesis tested was that a lower intake of natural 
protein rather than a lower level of total protein intake causes a retarded growth of 
height and head circumference in PKU children during the ﬁ rst 3 years of life. 
METHODS
The population studied consisted of 174 early (<21 days) diagnosed and 
continuously treated Caucasian Dutch PKU patients as reported in previous studies on 
growth in Dutch PKU patients 6;8.They were treated in the eight Dutch University child 
clinics. The study period ranged from 1 September 1974 to 31 December 1995.  None 
of the 174 patients needed to be excluded because of major congenital anomalies 
such as severe heart, lung renal or liver disease. 
We studied growth of height and head circumference in relation to the intake 
of protein and energy during the ﬁ rst three years of life. The period of 3 years was 
chosen because previous studies showed that this was the period in which the growth 
restriction was most evident 6. For the analyses of growth of head circumference, there 
were 13 dropouts because of insufﬁ cient data, leaving 161 subjects to be analysed. 
Because of insufﬁ cient dietary data, there were 41, 39 and 57 dropouts in the data on 
total protein, protein substitute and the natural protein intake, respectively, leaving 
133, 135 and 117 subjects to be analysed.
Height (cm) and head circumference (cm) were measured at time of diagnosis 
(in 74% before the age of 2 weeks), at the age of 6 months and yearly as close as 
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possible to the child’s birthday. Height and head circumference were converted into 
standard deviation scores (SDS) by subtracting the expected mean measurement for 
that age and sex and dividing by its standard deviation. As reference population we 
used the results of the National Dutch growth study 1955-199717.
To assess the individual protein intake, prescribed amounts of protein in the diet 
were registered at the same ages as for the anthropometric measurements. Data of 
the prescribed intake of total protein, natural protein and the protein equivalent from 
the protein substitute (calculated from the amount of prescribed protein substitute 
and the protein equivalent of the speciﬁ c protein substitute) were recorded. The 
relative contribution of natural protein in proportion to the protein equivalent of the 
protein substitute in the diet was calculated by dividing the natural protein intake by 
the intake of protein from the protein substitute. Mean individual intake of total and 
natural protein and protein substitute during the studied period was calculated by 
multiplying the daily intake (in g per kg per day) by the period (in days) during which 
the speciﬁ c amount was prescribed and dividing the sum of these products by the 
age (in days) at which the ﬁ nal anthropometric measurements were taken. 
Mean intake = [(intake1 * daysI)+(intake2 * daysII)+(intake3 * daysIII)+(intake4 * daysIV)] 
                                                                         ﬁ nal age
where intake is daily intake and 1 = 1 month, 2 = 6 months, 3 = 12 months and 4 = 24 
months of age and  I = 1-6 months, II = 6-12 months, III = 12-24 months and IV = 24-36 
months
Energy intake is an important factor in protein turnover and growth. Therefore, the 
individual mean energy intake was taken into account as a confounding factor. Mean 
energy intake was calculated in the same way as the mean of total protein, natural 
protein and protein substitute intake. After the ﬁ rst year of life energy intake is less 
precisely recorded and consequently prescribed energy intake cannot be assumed 
to match actual intake. Therefore, energy intake was only based on the prescriptions 
of the ﬁ rst year. Total energy intake during the ﬁ rst year was divided by weight at age 
1 year. To investigate probable effects of the clinical severity of the PAH deﬁ ciency on 
growth, Phe concentration - as measured at diagnosis - was regarded as an indicator 
of clinical severity of the PAH deﬁ ciency.
Table 1 shows total protein intake, natural protein intake and protein intake from 
the protein substitute, the relation between natural protein and protein substitute 
at the different time intervals, and the means of the different protein intakes and 
of the energy intake (for year 1). The ratio of natural protein and protein substitute 
during the ﬁ rst 6 months of life is signiﬁ cantly different from the other time intervals. 
The protein substitutes mainly used were: “PKU-1®” Milupa, Friedrichsdorf, Germany; 
“Fenyldon®”, Nutricia Nederland, Zoetermeer The Netherlands; “Phenyldon AM®” 
Nutricia Nederland, Zoetermeer The Netherlands; and “Phenystrict B®”, Friesche Vlag, 
Leeuwarden, The Netherlands.








Table 1. Protein intakes (mean and SD)   in the observation periods during the ﬁ rst 3 years of life 
and mean (SD) energy intake during the ﬁ rst year 
Source of intake Age  Mean intake  SD 
 (months) (g/kg per day) (g/kg per day)
Total protein 0-6 2,70 0,50
 6-12 2,36 0,51
 12-24 2,25 0,56
 24-36 2,20 0,65
Mean 0-36 2,33 0,42
Natural protein  0-6 1,22 0,53
 6-12 1,03 0,41
 12-24 0,97 0,46
 24-36 0,93 0,51
Mean 0-36 0,99 0,34
Protein substitute 0-6 1,46 0,58
 6-12 1,28 0,38
 12-24 1,26 0,34
 24-36 1,22 0,42
Mean 0-36 1,29 0,28
Ratio natural protein:  0-6 1,11* 0,91
protein substitute 6-12 0,87 0.45
 12-24 0,84 0,53
 24-36 0,84 0,62
Mean energy  intake  0-12 27 KJ per 2,6 KJ per
in ﬁ rst year of life  kg per day kg per day
* differs signiﬁ cantly from values at other time intervals.
Statistical analysis
Growth of height and head circumference was deﬁ ned as the change in SDS of 
height and the change in SDS of head circumference over the period investigated. 
These slopes were obtained by applying least-square regression analysis to the data 
of each patient separately, and expressed in SDS/year. The regression coefﬁ cients of 
the individual patients were then used in a linear regression analyses to investigate the 
possible relation between total protein intake, protein substitute and natural protein 
intake on the one hand, and growth of height and head circumference on the other 
hand. As potential confounding factors we considered the clinical severity of PAH 
deﬁ ciency and the energy intake during the ﬁ rst year of life. Since we considered that 
only a lower intake and not higher intake of protein mightlead to growth restriction, 
we considered a one tailed p-value of < 0.05 as statistically signiﬁ cant.
RESULTS
Only 90 patients used the same protein substitute during the complete study period 
(“PKU-1®” N=13, “Fenyldon®” N=42, “Fenyldon AM®” N=30, “Phenystrict B®” N=5). 
Figure 1 shows SDS of height and SDS of head circumference from diagnosis until 3 
years. For height growth, the mean slope was –0.057 SDS/year. For head circumference 
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Figure 1  Boxplots of SDS of (A) height and (B) head circumference from 1 to 36 months.
Table 2. Regression coefﬁ cients and 90% conﬁ dence interval (CI) of regression analyses of pro-
tein intake and growth.
Independent  Dependent  Unadjusted Adjusteda
variable variable Regression 90% CI Regression 90% CI
   coefﬁ cient  coefﬁ cient
Height growth Total   0.15* 0.00 to  0.30 0.09 -0.07 to 0.25
protein
Protein  0.05 -0.20 to 0.30 0.13 -0.12 to 0.38
substitute
Natural   0.04 -0.16 to 0.24 -0.02 -0.23 to 0.19
 protein
Head circumference  Total  0.30* 0.10 to 0.50 0.22* 0.02 to 0.42
growth protein
 Protein  -0.07 -0.35 to 0.21 0.07 -0.21 to 0.35
substitute
Natural  0.32* 0.09 to 0.55 0.28* 0.03 to 0.53
protein
aAdjusted for Phe and kcal/ weight
*signiﬁ cant (one sided p-value <0.05)
growth the mean slope was 0.29 SDS/year. 
Table 2 shows the relationships between intake and growth. After adjustment 
for the confounding factors, (i.e. energy intake during ﬁ rst year of life, severity of 
the deﬁ ciency of PAH) height growth was not signiﬁ cantly related to the total 
protein intake, natural protein intake, or protein substitute. After adjustment, head 
circumference growth was signiﬁ cantly related to total protein intake (p = 0.04) and 
natural protein intake (p = 0.035), but not to the amount of protein substitute. There 
was no signiﬁ cant relation between head circumference and height growth and 
diagnostic Phe concentration.









The present study addressed the question whether there is a relation between 
protein intake and growth in PKU patients. The most important ﬁ ndings were that the 
total protein intake and natural protein intake showed a signiﬁ cant relation with head 
circumference growth, but not with height growth during the ﬁ rst three years of age. In 
contrast, growth of height and head circumference did not correlate with the intake 
of energy during the ﬁ rst year, suggesting that nutritional demands were adequately 
met during this period. The third, and in our opinion most interesting ﬁ nding was that 
head circumference growth was affected by the intake of natural protein rather than 
total protein, and not by the intake of protein from the protein substitute. 
Two methodological issues need to be addressed before the results are discussed. 
First, when discussing the dietary data of the present study, it should be taken into 
account that the study is based on diet history data of the prescribed diet. This study, 
therefore, lacks information about the precise amount of protein consumed, which 
is not necessarily the same as the amount prescribed in the diet. However, even in 
the prospective study of Acosta et al, the prescribed intake was not the consumed 
intake15. Both our study and those of Acosta assume that there is a strong correlation 
between the prescribed and the consumed intake, especially during the ﬁ rst years 
of life. This seems a realistic assumption for various reasons. The frequency of dietary 
counselling is rather high during this period. During these consultations the various 
amounts of intake (natural protein, protein substitute) and energy intake are checked 
and the difﬁ culties encountered by the parents are discussed. Especially during the 
ﬁ rst years of life, parents can fairly easily control the nutritional intake of their child. 
During the ﬁ rst 3 years of age, parents control more or less easily nutritional intake of 
their child.
Secondly, the severity of the PAH deﬁ ciency was controlled for by the use of 
plasma Phe concentration at diagnosis. It should be taken into account that there is 
no gold standard for the severity of the PAH deﬁ ciency.
The ﬁ ndings of this study are in line with observations in non-PKU low-birth-weight 
infants, in which head circumference rather than height growth was positively 
affected by natural protein intake18. In non-PKU term infants, no clear relations were 
found19. It is not clear why head circumference growth rather than height growth is 
affected by natural protein intake in PKU patients.
The clinical importance of a small degree of height growth restriction can be 
questioned. However, head circumference could, especially during the ﬁ rst years of 
life, be regarded as an indicator of brain growth20. Moreover, a correlation was found 
between microcephaly in infants and mental retardation in later life21-23. Therefore, 
knowing that mental development in PKU patients still is not equal to that in non-PKU 
individuals, head circumference growth in PKU infants should be monitored closely 
and needs to be optimised in order to try to achieve maximum patient IQ in later 
life.
We hypothesised that in PKU patients growth rate is related to the intake of natural 
protein rather than the total protein intake. Although there is a signiﬁ cant relation 
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between head circumference growth and total protein intake, of the two components 
that compose total protein only the relation with natural protein intake was signiﬁ cant 
and not the relation with protein substitute. 
It could be hypothesised that the clinical severity of PAH deﬁ ciency affects both 
head circumference growth and the intake of natural protein (by its aims of treatment), 
and that, therefore, a relation was found between head circumference and (natural) 
protein intake. The clinical severity of PAH deﬁ ciency seemed to reduce the strength 
of the relations found between head circumference and the protein intake to a small 
degree. At the same time, however, no signiﬁ cant relation was found between the 
clinical severity of the PAH deﬁ ciency and head circumference (p = 0,20), suggesting 
that the retarded head circumference growth did not stem from the clinical severity 
of the PAH deﬁ ciency. Since natural protein only accounts for only a minor part of the 
total protein, the present data strongly suggest that an increase in total protein does 
not affect growth in PKU children as it increases the intake of natural protein only to 
a small degree. 
The lack of a relation with the protein substitutes can be due to various reasons. For 
example, the composition of the protein substitutes varies between the companies 
that manufactured the substitutes during these years. This study comprised a large 
time window in which the composition of the protein substitutes changed more than 
once in terms of both  the amino acids and the other substances that constitute 
the protein substitute. For example, some substitutes contained carnitine, others did 
not; some manufacturers included long chain poly unsaturated fatty acids, others 
introduced these at a later date. The numbers of patients using a speciﬁ c protein 
substitute during the entire study period where too small to allow a detailed statistical 
analysis on differences in growth parameters of patients using different substitutes. 
The relationship between natural protein and protein from substitute differs between 
intervals studied. Especially during the ﬁ rst six months of life, natural protein intake is 
higher, whereas in the years thereafter the relationship between natural protein and 
protein from the protein substitute no longer changes signiﬁ cantly. However, this does 
not seem to explain the signiﬁ cant relation found between natural protein intake and 
growth over the ﬁ rst 3 years of life, as during the ﬁ rst 6 months of life neither natural 
protein intake nor the protein substitutes correlated signiﬁ cantly with growth. 
The data of this study suggest that the composition of the protein substitutes used 
may less optimal in terms of the composition of natural protein. One reason may be 
that the metabolic use is less effective for the amino acids supplied by the protein 
substitute than for the protein derived from milk or egg9;24. Especially when the daily 
intake of protein substitute is not adequately distributed over the day, plasma amino 
acid concentrations rise more rapidly, and amino acids are used for oxidation rather 
than protein synthesis25;26.
Factors other than amino acids, however, may be important as well. Recent studies 
showed that deﬁ ciencies of long chain polyunsaturated fatty acids may also cause 
a lower growth rate of head circumference. For example, the ratio of arachidonic 
acid and docosahexaenoic acid seems to be important for the increase in head 
circumference in young infants 27. Other studies pointed to a clear deﬁ cit of the long 








chain polyunsaturated fatty acids in the protein substitute given to PKU children in the 
past, offering a good alternative explanation10;28.
Apart from this, with the knowledge that excessive protein intake in early life is 
related to a number of negative effects in later life (obesity, renal dysfunction and 
even reduced intellectual outcome), caution against too high a protein intake in 
(PKU) children is warranted3. 
In conclusion, our study showed that height growth is not clearly related to protein 
intake and that the amount of natural protein intake, rather than the total protein 
intake seems an important factor in head circumference growth. Therefore, in 
investigating the association between growth and protein intake in PKU patients, not 
only the amount of total protein, but also the amount of natural protein and protein 
substitute should be taken into account. We did not ﬁ nd a relation between growth 
and the intake of protein substitute. The relation with natural protein intake suggests 
that further improvement of the protein substitute, to make it more comparable 
to natural protein, rather than an increase in intake of total protein is important to 
achieve optimal (head circumference) growth in PKU children. 
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